ESMO 2024

New updates from the innovative I-SPY program

Therapy de-escalation and balancing individualized therapy management in early breast cancer patients

4-year update of Riboclib in EBC - can we avoid chemo?

Escalation, De-escalation and management of therapy: how to identify the best treatment option for our patients?

Hypofractionation in early breast cancer

Survival benefit reported with Pembro

Survival data from WSG-TP-II

Physical exercise and oncological outcome

Overall survival advantage for Pembrolizumab in early TNBC

Registry data from France - no break in endocrine therapy in young patients

Compliance is everything

Endocrine therapy in triple-positive premenopausal patients

Evaluation of the patient collective under 40 years

4-year landmark data

Ribociclib in younger patients

Update on NATALEE in young patients

Update on NATALEE in young patients

Physical exercise and oncological outcome

De-Escalation in the metastatic setting

T-DXD for everyone - what is the minimal threshold for HER2: How to sequence therapies?

TILs and overall survival in the shortHER trial

Brain imaging screening in MBC patients

No benefit of Akt-inhibition in mTNBC

Highlights of ESMO 2024

Keep the patients trained!

PIK3CA is not a vaild pathway in triple-negative breast cancer

Akt-inhibition works with HR+ but not with mTNBC

Brain imaging screening in MBC patients

New approaches to treat 1L patients mTNBC

TILs e sopravvivenza nello studio shortHER

PIK3CA is not a vaild pathway in triple-negative breast cancer

Punti salienti di ESMO 2024

Nuovi approcci per il trattamento dei pazienti 1L mTNBC

Promosing results for the new ADC in HR+ - negative results for pAKT inhibitors in mTNBC: we have to better understand the biology.

New first choice treatment for patients with brain metastases?

ctDNA data and clinical efficacy of SG

Soon no chemotherapy for triplenegative mBC

T-Dxd in patients with and without brain metastases

Study impression in HR+/HER2- mBC progressing after two lines of therapy

Efficacy of T-Dxd in patients with brain metastasis

T-Dxd in BrainMets

Primary systematic treatment of active brain metastases

Endocrine-based therapy in combination with dual blockade

High sensitivity testing as outcome predictor for T-DXD in mBC

Her3-Dxd - new application area for ADCs

Outstanding efficacy of T-Dxd in CNS meastases

Optimization treatment with ADCs in endocrine therapy

HER3- DXd in the ICARUS Breast-01 study

Primary results of DB-12

Impression d'étude dans le cancer du sein métastatique HR+/HER2- progressant après deux lignes de traitement

Impressione dello studio nel carcinoma mammario metastatico HR+/HER2- in progressione dopo due linee di terapia

Risultati primari dello studio DB-12

Optimization treatment with ADCs in endocrine therapy

Endocrine resistance to CDK4/6 inhibitors

CTCs as surrogate markers for endocrine therapy

Screening for brain metastases – what do doctors and patients think about it?

Niraparib in ovarian cancer without survival benefit

Overview on the perioperative treatment landscape

The importance of markers for patient management

Significant CNS protection by osimertinib

Getting rid of it will save your life!

ctDNA - a promising new biomarker in early lung cancer

Neoadjuvant vs. Perioperative

Should we move away from adjuvant immunotherapy?

Durvalumab did not meet primary endpoint in CCTG BR.31 trial

Perioperative IO Therapy - adjuvant necessary?

BR31: The first negative adjuvant study in resected NSCLC

Negative adjuvant CPI trial

Eliminarlo potrebbe salvarti la vita

BR31: La première étude d’immunothérapie adjuvante négative dans les CBNPC réséqués

Should we move away from adjuvant immunotherapy?

Durvalumab non ha raggiunto l'endpoint primario nello studio CCTG BR.31

New 1st line treatment opportunities in advanced stage NSCLC

Update on genetic alterations - ALK / ROS / KRAS / BRAF

Pieces of evidence in the EGFR domain

Early mechanisms of resistance from MARIPOSA

Sustained OS at 2nd interim analysis in MARIPOSA-2

NVALT: 1st attempt to reduce dose of pembrolizumab and limit the financial burden

Second interim analysis of MARIPOSA-2

1st line encorafenib + binimetinib: combination is very active but PFS very different

Half of the dose - same activity: provocative findings from NVALT-30

Two sometimes may be better than one!

Patterns of resistance in MARIPOSA trial

The next generation of ROS inhibitors

Adding anti-LAG-3 doesn't seem to being worth it

Survival Data with Amivantamab for EGFR Alteration

NVL-655: a promising new ALK inhibitor

4th generation with ALK-alterations

MARIPOSA - lower rate of MET amplification and EGFR resistance mutation

Bispecific antibodies better than ADCs?

Optimizing the dose of immunotherapy

The next generation of ALK inhibitors

Quality of life with Telisotuzumab in LUMINOSITY

RELATIVITY-104: efficacy of anti immunotherapy

Promising signal for anti-TIGIT + anti-PD-1 with PD-L1 > 50 %

NVL-520 for ROS alteration - already best in class?

Quality of life with Telisotuzumab in LUMINOSITY

Second interim analysis of MARIPOSA-2

Patterns of resistance in MARIPOSA trial

CBNPC muté BRAF en 1ère ligne : encorafenib + binimetinib : association très active mais la SSP très différente selon les études

Optimizing the dose of immunotherapy

Aggiungere l'anti-LAG-3 non sembra valerne la pena

2 a volte sono meglio di uno

NVALT: Première tentative pour réduire la dose de pembrolizumab dans les CBNPC de stade IV et réduire le cout du traitement

RELATIVITY-104: efficacy of anti immunotherapy

New data on SCLC and mesothelioma

Subset analysis from ADRIATIC

New standard of care in LS-SCLC

Neuer Behandlungsstandard beim LS-SCLC

Is the radiologist redundant in mesothelioma RECIST measurements

Response assessment in mesothelioma - can AI help?

Is the radiologist redundant in mesothelioma RECIST measurements

Doublet therapy in prostate cancer: Practice changing or rather practice informing?

Practice changing- Big Revival - Or just a Splish? Don't forget the bone protection!

IO in mCRPC: Let's move on to the next substance?!

New PSMA-ligand

Molecular analysis from PEACE-1

Immunotherapy for prostate cancer

Upfronts in personal

We come in PEACE

New hormone therapy for mCRPC

Radium223 Prior to Docetaxel Improves Quality of Life in Bone-Dominant mCRPC: Findings from the RAPSON Phase 2 Trial

Radium and enzalutamide in mCRPC - final results

Darolutamide in mHSPC

Not a Patch on ADT?

Was it a splash or was it a splish?

Did CONTACT make any contact?

Metformin in mHSPC

LuPSMA moves UpFront

Radium-223 an option again?

PSMA-radioligand - the first study of its kind

Radium and enzalutamide in mCRPC - final results

PSMA-radioligand - the first study of its kind

Molecular analysis from PEACE-1

New PSMA-ligand

Microbiome transplantation in RCC – how to tailor this therapy for our patients

Establishing ICI as standard of care in RCC

Where is the right place for HIF inhibitors in advanced RCC therapy?

IO after IO – is there a role for sequential immunotherapy in RCC?

Treating nccRCC - Nivo/Ipi as a new potential option

TKI monotherapy remains standard in 2ndL

Stool transplantation is the shit

New SOC for non-cc-RCC?

Opening a new way of treatment in MIBC

mRCC ≥ 1L? News on intensification?

IO therapy is standard for nccRCC

Ipi-Nivo in nccRCC

The role of sequencing therapy in RCC

Glycoproteins as Predictive Biomarkers for Nivolumab Plus Cabozantinib Response in Advanced Renal Cell Carcinoma

HIF-2a inhibitors are on their way

Sequencing checkpoint inhibitors - the story is over

FMT in a novel setting

My view on SUNNIFORECAST

CPI - modification / prediction - fact or fantasy?

Immunotherapy for nccRCC

SUNNIFORECAST - rain or shine?

Updated survival results

Tratamiento del nccRCC - Nivo/Ipi como nueva opción potencial

Sequencing checkpoint inhibitors - the story is over

Se abre una nueva vía de tratamiento en el cáncer de vejiga con invasión muscular

Biomarkers in Bladder cancer - the road to individualized therapy

Chemo + IO in the perioperative setting - new standard of care

Encouraging data - but we need more data!

Pretzel therapy for superficial UC

Is intravesical therapy as easy as baking a pretzel?

mUC - new ADC's?

Practice changing new data in Bladder cancer at ESMO24

Nivolumab Plus Gemcitabine-Cisplatin Maintains Quality of Life in Metastatic Urothelial Carcinoma

New data on ADCs in bladder cancer

NIAGARA sets new standard

New standard: perioperative MIBC-NIAGARA

EV + Pembro is broadly effective

Value of ctDNA

A new way to give chemo for patients who are ineligible for neoadj therapy

TAR200 intravesical +/- Cetrelimab in HR (N)MIBC

Nuevos datos sobre las ADC en el cáncer de vejiga

Practice changing new data in Bladder cancer at ESMO24

A new way to give chemo for patients who are ineligible for neoadj therapy